225 related articles for article (PubMed ID: 36189258)
21. Cancer-Testis Gene Expression in Hepatocellular Carcinoma: Identification of Prognostic Markers and Potential Targets for Immunotherapy.
Zhang YP; Bao ZW; Wu JB; Chen YH; Chen JR; Xie HY; Zhou L; Wu J; Zheng SS
Technol Cancer Res Treat; 2020; 19():1533033820944274. PubMed ID: 32715976
[TBL] [Abstract][Full Text] [Related]
22. Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma.
Wang J; Ling S; Ni J; Wan Y
BMC Cancer; 2022 Jun; 22(1):638. PubMed ID: 35681134
[TBL] [Abstract][Full Text] [Related]
23. CXCL2/10/12/14 are prognostic biomarkers and correlated with immune infiltration in hepatocellular carcinoma.
Lin T; Zhang E; Mai PP; Zhang YZ; Chen X; Peng LS
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34085699
[TBL] [Abstract][Full Text] [Related]
24. Molecular subtypes, prognostic and immunotherapeutic relevant gene signatures mediated by DNA methylation regulators in hepatocellular carcinoma.
Shi R; Zhao H; Zhao S; Yuan H
Aging (Albany NY); 2022 Jun; 14(12):5271-5291. PubMed ID: 35771147
[TBL] [Abstract][Full Text] [Related]
25. Malignant cell receptor-ligand subtypes guide the prediction of prognosis and personalized immunotherapy of liver cancer.
Wu J; Wu C; Cai X; Li P; Lin J; Wang F
Aging (Albany NY); 2024 Jan; 16(2):1712-1732. PubMed ID: 38244584
[TBL] [Abstract][Full Text] [Related]
26. Chemokine clouding and liver cancer heterogeneity: Does it impact clinical outcomes?
Ahmad M; Dhasmana A; Harne PS; Zamir A; Hafeez BB
Semin Cancer Biol; 2022 Nov; 86(Pt 3):1175-1185. PubMed ID: 35189322
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma.
Xie F; Bai Y; Yang X; Long J; Mao J; Lin J; Wang D; Song Y; Xun Z; Huang H; Yang X; Zhang L; Mao Y; Sang X; Zhao H
Int Immunopharmacol; 2020 Dec; 89(Pt A):107135. PubMed ID: 33189609
[TBL] [Abstract][Full Text] [Related]
28. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
Mo Z; Liu D; Rong D; Zhang S
Front Immunol; 2021; 12():611058. PubMed ID: 33679749
[No Abstract] [Full Text] [Related]
29. Analysis of the impact of fatty acid metabolism on immunotherapy for hepatocellular carcinoma.
Wang J; Jin X
Ann Hepatol; 2023; 28(6):101148. PubMed ID: 37643716
[TBL] [Abstract][Full Text] [Related]
30. Molecular subtypes based on DNA sensors predict prognosis and tumor immunophenotype in hepatocellular carcinoma.
Lin HS; Pang WP; Yuan H; Kong YZ; Long FL; Zhang RZ; Yang L; Fang QL; Pan AP; Fan XH; Li MF
Aging (Albany NY); 2023 Jul; 15(14):6798-6821. PubMed ID: 37451838
[TBL] [Abstract][Full Text] [Related]
31. Development and validation of a CTNNB1-associated metabolic prognostic model for hepatocellular carcinoma.
Huo J; Wu L; Zang Y
J Cell Mol Med; 2021 Jan; 25(2):1151-1165. PubMed ID: 33300278
[TBL] [Abstract][Full Text] [Related]
32. Integrated Machine Learning and Bioinformatic Analyses Constructed a Novel Stemness-Related Classifier to Predict Prognosis and Immunotherapy Responses for Hepatocellular Carcinoma Patients.
Chen D; Liu J; Zang L; Xiao T; Zhang X; Li Z; Zhu H; Gao W; Yu X
Int J Biol Sci; 2022; 18(1):360-373. PubMed ID: 34975338
[TBL] [Abstract][Full Text] [Related]
33. Molecular subtypes of disulfidptosis-regulated genes and prognosis models for predicting prognosis, tumor microenvironment infiltration, and therapeutic response in hepatocellular carcinoma.
Qu J; Guan H; Zheng Q; Sun F
Int J Biol Macromol; 2024 Mar; 261(Pt 1):129584. PubMed ID: 38246443
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.
Hao X; Zheng Z; Liu H; Zhang Y; Kang J; Kong X; Rong D; Sun G; Sun G; Liu L; Yu H; Tang W; Wang X
Redox Biol; 2022 Oct; 56():102463. PubMed ID: 36108528
[TBL] [Abstract][Full Text] [Related]
35. Tumor biology, immune infiltration and liver function define seven hepatocellular carcinoma subtypes linked to distinct drivers, survival and drug response.
Wu R; Gao Y; Zhao X; Guo S; Zhou H; Zhang Y; Hou Y; Mei L; Zhi H; Wang P; Li X; Ning S; Zhang Y
Comput Biol Med; 2023 Dec; 167():107593. PubMed ID: 37883849
[TBL] [Abstract][Full Text] [Related]
36. Deciphering the immunological and prognostic features of hepatocellular carcinoma through ADP-ribosylation-related genes analysis and identify potential therapeutic target ARFIP2.
Jiang F; Xu Y; Jiang Z; Hu B; Lv Q; Wang Z
Cell Signal; 2024 May; 117():111073. PubMed ID: 38302034
[TBL] [Abstract][Full Text] [Related]
37. Tumor suppressor gene mutations correlate with prognosis and immunotherapy benefit in hepatocellular carcinoma.
Liu Z; Liu L; Guo C; Yu S; Meng L; Zhou X; Han X
Int Immunopharmacol; 2021 Dec; 101(Pt B):108340. PubMed ID: 34789428
[TBL] [Abstract][Full Text] [Related]
38. Immune cell infiltration and immunotherapy in hepatocellular carcinoma.
Jiang Y; Lin L; Lv H; Zhang H; Jiang L; Ma F; Wang Q; Ma X; Yu S
Math Biosci Eng; 2022 May; 19(7):7178-7200. PubMed ID: 35730302
[TBL] [Abstract][Full Text] [Related]
39. Deciphering the tumour immune microenvironment of hepatocellular carcinoma.
Liu S; Jia M; Dai R
Scand J Immunol; 2023 Nov; 98(5):e13327. PubMed ID: 38441331
[TBL] [Abstract][Full Text] [Related]
40. Establishing a signature based on immunogenic cell death-related gene pairs to predict immunotherapy and survival outcomes of patients with hepatocellular carcinoma.
Ma J; Kuang L; Zhao R
Aging (Albany NY); 2022 Dec; 14(23):9699-9714. PubMed ID: 36516498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
